Revolution Medicines, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Revolution Medicines, Inc. has filed its 2023 annual report (10-K), detailing its financial performance and significant corporate events, including the acquisition of EQRx Inc.</b>

AI Summary

Revolution Medicines, Inc. (RVMDW) filed a Annual Report (10-K) with the SEC on February 26, 2024. Revolution Medicines, Inc. filed its 2023 Form 10-K on February 26, 2024. The filing covers the fiscal year ending December 31, 2023. Key events during the period include the acquisition of EQRx Inc. on November 9, 2023. The company's fiscal year end is December 31. Revolution Medicines, Inc. is incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking Revolution Medicines, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Revolution Medicines' financial health, operational activities, and strategic initiatives for the fiscal year 2023, including the impact of the EQRx acquisition. Investors and stakeholders can use this report to assess the company's progress, risks, and future outlook in the biotechnology sector, particularly concerning its drug development pipeline and market position.

Risk Assessment

Risk Level: medium — Revolution Medicines, Inc. shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently risky due to long development cycles, high failure rates in clinical trials, and significant regulatory hurdles. The acquisition of EQRx Inc. also introduces integration risks and potential financial strain.

Analyst Insight

Monitor the integration of EQRx Inc. and the progress of Revolution Medicines' drug development pipeline for future growth indicators.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period covered by the 10-K filing)
• 2024-02-26 — Filing Date (Date the 10-K was filed)
• 2023-11-09 — EQRx Acquisition Date (Date Revolution Medicines acquired EQRx Inc.)

Key Players & Entities

• Revolution Medicines, Inc. (company) — Filer name
• EQRx Inc. (company) — Acquired company
• 2023-12-31 (date) — Fiscal year end
• 2024-02-26 (date) — Filing date
• 2023-11-09 (date) — Acquisition date of EQRx Inc.
• DE (jurisdiction) — State of incorporation

FAQ

Risk Factors

• Acquisition Integration Risk [high — financial]: The integration of EQRx Inc. may not be successful, leading to disruptions in operations, loss of key personnel, and failure to realize anticipated synergies.
• Drug Development and Approval Risk [high — regulatory]: The company's drug candidates are in various stages of development and subject to extensive clinical trials and regulatory review, with no assurance of successful approval or commercialization.
• Competition Risk [medium — market]: The biotechnology and pharmaceutical markets are highly competitive, with many companies developing therapies for similar diseases, which could impact market share and pricing.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-26: 10-K Filing Date — Date the annual report was officially submitted to the SEC.
• 2023-11-09: Acquisition of EQRx Inc. — Significant corporate event impacting the company's structure and operations.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock $0.0001 Par Value per Share RVMD The Nasdaq
• $26.75 — lobal Select Market on June 30, 2023 of $26.75 per share. The number of shares of th

Filing Documents

• rvmd-20231231.htm (10-K) — 3621KB
• rvmd-ex4_3.htm (EX-4.3) — 77KB
• rvmd-ex4_5.htm (EX-4.5) — 880KB
• rvmd-ex4_4a.htm (EX-4.4(A)) — 501KB
• rvmd-ex21_1.htm (EX-21.1) — 10KB
• rvmd-ex23_1.htm (EX-23.1) — 3KB
• rvmd-ex31_1.htm (EX-31.1) — 15KB
• rvmd-ex31_2.htm (EX-31.2) — 15KB
• rvmd-ex32_1.htm (EX-32.1) — 8KB
• rvmd-ex32_2.htm (EX-32.2) — 8KB
• rvmd-ex97.htm (EX-97) — 42KB
• img28365936_0.jpg (GRAPHIC) — 14KB
• img28365936_1.jpg (GRAPHIC) — 79KB
• img28365936_2.jpg (GRAPHIC) — 39KB
• img28365936_3.jpg (GRAPHIC) — 32KB
• img28365936_4.jpg (GRAPHIC) — 58KB
• img28365936_5.jpg (GRAPHIC) — 122KB
• img28365936_6.jpg (GRAPHIC) — 27KB
• img28365936_7.jpg (GRAPHIC) — 54KB
• img28365936_8.jpg (GRAPHIC) — 294KB
• 0000950170-24-020145.txt (&nbsp;) — 16361KB
• rvmd-20231231.xsd (EX-101.SCH) — 1713KB
• rvmd-20231231_htm.xml (XML) — 2277KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 33 Item 1B. Unresolved Staff Comments 82 Item 1C. Cybersecurity 82 Item 2.

Properties

Properties 83 Item 3.

Legal Proceedings

Legal Proceedings 84 Item 4. Mine Safety Disclosures 84 PART II 85 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 85 Item 6. [Reserved.] 85 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 86 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 98 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 98 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 127 Item 9A.

Controls and Procedures

Controls and Procedures 127 Item 9B. Other Information 127 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 128 PART III 129 Item 10. Directors, Executive Officers and Corporate Governance 129 Item 11.

Executive Compensation

Executive Compensation 129 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 129 Item 13. Certain Relationships and Related Transactions, and Director Independence 129 Item 14. Principal Accounting Fees and Services 129 PART IV 130 Item 15. Exhibits, Financial Statement Schedules 130 Item 16. Form 10-K Summary 133

Signatures

Signatures 134 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would," and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the scope, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials; the scope, progress, results and costs related to the research and development of our pipeline; the timing of and costs involved in obtaining and maintaining regulatory approval for any of current or future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; our expectations regarding the potential market size and size of the potential patient populations for our product candidates

Bus iness

Item 1. Bus iness. Overview We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which we refer to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which we refer to as RAS Companion Inhibitors. Our RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Our RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on our RAS(ON) Inhibitors. RAS(ON) Inhibitors Our RAS(ON) Inhibitors are based on our proprietary tri-complex technology platform, which enables a highly differentiated approach to inhibiting the active, GTP-bound form of RAS, which we refer to as RAS(ON). We are developing a portfolio of compounds that we believe are the first and only RAS(ON) Inhibitors to use this mechanism of action. We believe that direct inhibitors of RAS(ON) suppress cell growth and survival and are less susceptible to adaptive resistance mechanisms recognized for RAS(OFF) Inhibitors. We are evaluating our RAS(ON) Inhibitors alone and in combination with other drugs and investigational drug candidates, including with other RAS(ON) Inhibitors in RAS(ON) Inhibitor doublet regimens. We are advancing a deep pipeline of RAS(ON) Inhibitors, i

View Full Filing

View this 10-K filing on SEC EDGAR